Tasquinimod (ABR-215050), an oral immunomodulatory compound, reportedly affects the accumulation and function of tumor-suppressive myeloid cells, MDSCs, and M2-like TAMs via targeting the inflammatory protein S100A9 [283,284,285]. Here, S100A9 is linked to neoplasm.